4 - GENELUX Corp (0001231457) (Issuer)

4 - GENELUX Corp (0001231457) (Issuer)

4 - GENELUX Corp (0001231457) (Issuer)

4 - GENELUX Corp (0001231457) (Issuer)

4 - GENELUX Corp (0001231457) (Issuer)

4 - GENELUX Corp (0001231457) (Issuer)

4 - GENELUX Corp (0001231457) (Issuer)

4 - GENELUX Corp (0001231457) (Issuer)

4 - GENELUX Corp (0001231457) (Issuer)

Recently, on June 7, 2024, Michael L Berger, a significant figure at Air Transport Services Group Inc, made a notable insider purchase. Berger bought $49,830 worth of shares, acquiring 3,996 units at a price of $12.47 per share. This transaction increased his direct ownership by 4% to 103,705 units as reported in the SEC Form 4 here. Examining other insider actions within the company can sometimes reveal intriguing patterns that might offer insights for investors. Looking back at previous transactions, we see a series of insider activities at Air Transport Services Group Inc: In March 2024, Dominick Jeffrey A. filed an SEC Form 4, indicating a notable transaction date in which actions were

Guggenheim initiated coverage of Genelux with a rating of Buy and set a new price target of $8.00

ROTH MKM initiated coverage of Genelux with a rating of Buy and set a new price target of $10.00

H.C. Wainwright initiated coverage of Genelux with a rating of Buy and set a new price target of $35.00

Maxim Group initiated coverage of Genelux with a rating of Buy and set a new price target of $40.00

The Benchmark Company initiated coverage of Genelux with a rating of Speculative Buy and set a new price target of $10.00

4 - GENELUX Corp (0001231457) (Issuer)

4/A - GENELUX Corp (0001231457) (Issuer)

4 - GENELUX Corp (0001231457) (Issuer)

4 - GENELUX Corp (0001231457) (Issuer)

4 - GENELUX Corp (0001231457) (Issuer)

4 - GENELUX Corp (0001231457) (Issuer)

4 - GENELUX Corp (0001231457) (Issuer)

4 - GENELUX Corp (0001231457) (Issuer)

4 - GENELUX Corp (0001231457) (Issuer)

4 - GENELUX Corp (0001231457) (Issuer)

10-Q - GENELUX Corp (0001231457) (Filer)

8-K - GENELUX Corp (0001231457) (Filer)

10-Q - GENELUX Corp (0001231457) (Filer)

8-K - GENELUX Corp (0001231457) (Filer)

8-K - GENELUX Corp (0001231457) (Filer)

ARS - GENELUX Corp (0001231457) (Filer)

DEFA14A - GENELUX Corp (0001231457) (Filer)

DEF 14A - GENELUX Corp (0001231457) (Filer)

8-K - GENELUX Corp (0001231457) (Filer)

424B5 - GENELUX Corp (0001231457) (Filer)

Frazier Life Sciences (FLS), a longstanding investment firm focused on innovative therapeutics, today announced the addition of industry veterans John Smither and Jim Williams, MBA, as Senior Advisors. "John and Jim are seasoned veterans in the field, and each brings a differentiated skill set that will enable us to strengthen our execution across the private and public investment strategies of the firm," said Patrick Heron, Managing Partner at FLS. John has over 25 years of financial experience in the biopharmaceutical industry. Before joining FLS, John served as the Chief Financial Officer of Arcutis Biotherapeutics, Inc., where he led the company's successful initial public offering

WESTLAKE VILLAGE, Calif., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ:GNLX), a late clinical-stage immuno-oncology company, today announced financial results for the third quarter of 2024 and provided general business updates. The Company initiated its second lung cancer trial, a US-based, Phase 2 trial (VIRO-25) treating patients with recurrent advanced or metastatic non-small cell lung cancer (NSCLC) with Olvi-Vec, followed by platinum-doublet chemotherapy + immune checkpoint inhibitor. Additionally, a Phase 1b/2 lung cancer trial is ongoing in recurrent small cell lung cancer (SCLC) in China which is co-sponsored with Newsoara BioPharma Co., Ltd. Both trials

– VIRO-25 trial to assess efficacy & safety of olvimulogene nanivacirepvec (Olvi-Vec) & platinum-doublet + physician's choice of immune checkpoint inhibitor compared to docetaxel in recurrent non-small cell lung cancer – – Trial represents second indication in the clinic for Olvi-Vec via systemic administration – – Interim readout expected mid-2025 – WESTLAKE VILLAGE, Calif., Oct. 22, 2024 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ:GNLX), a late-stage clinical immuno-oncology company, today announced that the first patient has been dosed in the U.S.-based Phase 2 (VIRO-25) trial evaluating systemically delivered Olvi-Vec in patients with recurrent non-small cell lung cancer (NSCLC)

WESTLAKE VILLAGE, Calif., Oct. 09, 2024 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ:GNLX), a late clinical-stage immuno-oncology company, today announced that Thomas Zindrick, President, CEO and Chairman of the Board, will participate at the 2024 Maxim Healthcare Virtual Summit taking place October 15-17, 2024. Mr. Zindrick will discuss clinical-stage programs, recent announcements, and upcoming milestones in a fireside chat with Jason McCarthy, Ph.D., Senior Managing Director, Head of Biotechnology Research, which is scheduled for 2:00 pm E.T. on October 15, 2024. About Genelux CorporationGenelux is a late clinical-stage biopharmaceutical company focused on developing a pipeline of

WESTLAKE VILLAGE, Calif., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ:GNLX), a late clinical-stage immuno-oncology company, today announced that Thomas Zindrick, President, Chairman and CEO, will discuss clinical-stage programs, recent announcements, and upcoming milestones in a fireside chat at the H.C. Wainwright Global Healthcare Conference, taking place September 9-11, 2024, in New York City, New York. The conversation with Emily Bodnar, Vice President, Equity Research and H.C. Wainwright Biotechnology Analyst, is scheduled to begin at 12:30 p.m. ET on Wednesday, September 11, 2024. A webcast link for the H.C. Wainwright Conference event will be available at https:/

WESTLAKE VILLAGE, Calif., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ:GNLX), a late clinical-stage immuno-oncology company, today announced financial results for the second quarter of 2024 and provided general business updates.   "The past quarter has continued to be transformative for the company as we completed a key financing expected to provide runway through three trial readouts, including our ongoing Phase 3 trial in platinum resistant/refractory ovarian cancer," said Thomas Zindrick, President, Chairman and CEO of Genelux. "Beyond our pivotal Phase 3 trial, we look to provide interim data for systemic delivery of Olvi-Vec in both small and non-small cell lung canc

WESTLAKE VILLAGE, Calif., July 30, 2024 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ:GNLX), a late clinical-stage immuno-oncology company, today announced that Thomas Zindrick, President, CEO and Chairman, will discuss clinical-stage programs, recent announcements, and upcoming milestones in a fireside chat at BTIG's Virtual Biotechnology Conference 2024. The conversation with Kaveri Pohlman, PhD, Director and BTIG Biotechnology Analyst, is scheduled to begin at 12:00 p.m. ET on Tuesday, August 6, 2024. About Genelux CorporationGenelux is a late clinical-stage biopharmaceutical company focused on developing a pipeline of next-generation oncolytic immunotherapies for patients suffering

WESTLAKE VILLAGE, Calif., May 24, 2024 (GLOBE NEWSWIRE) -- Genelux Corporation (Genelux) (NASDAQ:GNLX), a late clinical-stage immuno-oncology company, today announced the pricing of an underwritten offering of 6,875,000 shares of its common stock and accompanying warrants to purchase 6,875,000 shares of its common stock at a combined offering price of $4.00 per share and accompanying warrant, in each case before underwriting discounts and commissions. Each warrant will have an exercise price of $5.25 per share, will be immediately exercisable following the closing of the offering and will expire five years from the date of issuance. Gross proceeds to Genelux from the offering are expected

WESTLAKE VILLAGE, Calif., May 23, 2024 (GLOBE NEWSWIRE) -- Genelux Corporation (Genelux) (NASDAQ:GNLX), a late clinical-stage immuno-oncology company, today announced that it has commenced an underwritten public offering of its common stock and accompanying warrants. All shares of common stock and accompanying warrants are being offered by Genelux. In addition, Genelux expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the number of shares of common stock sold in connection with the offering (including shares underlying the warrants). Guggenheim Securities is acting as sole book-running manager for the offering. Newbridge Securities Corporation is act

WESTLAKE VILLAGE, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ:GNLX), a late clinical-stage immuno-oncology company, today announced financial results for the first quarter of 2024 and provided general business updates.   "Our pivotal Phase 3 registration trial of Olvi-Vec in platinum resistant/refractory ovarian cancer continues to enroll patients," said Thomas Zindrick, President, Chairman and CEO of Genelux. "Looking ahead, we are excited about advancing Olvi-Vec into additional cancer indications through intravenous administration, a physician-preferred route of delivery, and seeking to further validate our hypothesis that Olvi-Vec may reverse resistance to pla

Recently, on June 7, 2024, Michael L Berger, a significant figure at Air Transport Services Group Inc, made a notable insider purchase. Berger bought $49,830 worth of shares, acquiring 3,996 units at a price of $12.47 per share. This transaction increased his direct ownership by 4% to 103,705 units as reported in the SEC Form 4 here. Examining other insider actions within the company can sometimes reveal intriguing patterns that might offer insights for investors. Looking back at previous transactions, we see a series of insider activities at Air Transport Services Group Inc: In March 2024, Dominick Jeffrey A. filed an SEC Form 4, indicating a notable transaction date in which actions were

Benchmark analyst Bruce Jackson reiterates Genelux (NASDAQ:GNLX) with a Speculative Buy and maintains $25 price target.

Genelux (NASDAQ:GNLX) underwent analysis by 4 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish. Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 2 2 0 0 0 Last 30D 0 1 0 0 0 1M Ago 1 0 0 0 0 2M Ago 1 1 0 0 0 3M Ago 0 0 0 0 0 The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $29.75, a high estimate of $32.00, and a low estimate of $25.00. This current average represents a 8.46% decrease from the previous

Benchmark analyst Bruce Jackson maintains Genelux (NASDAQ:GNLX) with a Speculative Buy and lowers the price target from $30 to $25.

Gainers Innovative Eyewear (NASDAQ:LUCY) shares moved upwards by 421.5% to $0.97 during Monday's regular session. The company's market cap stands at $16.9 million. OneMedNet (NASDAQ:ONMD) shares moved upwards by 55.78% to $2.29. The company's market cap stands at $54.6 million. Qilian Intl Hldg Gr (NASDAQ:QLI) shares moved upwards by 37.59% to $0.91. The company's market cap stands at $32.4 million. Onconetix (NASDAQ:ONCO) shares moved upwards by 29.7% to $0.18. The market value of their outstanding shares is at $4.0 million. TransCode Therapeutics (NASDAQ:RNAZ) shares moved upwards by 28.77% to $1.79. The company's market cap stands at $11.8 million. MultiPlan (NYSE:MPLN) stock rose 2

Gainers Cue Health (NASDAQ:HLTH) stock moved upwards by 32.4% to $0.12 during Monday's pre-market session. The market value of their outstanding shares is at $19.8 million. SCWorx (NASDAQ:WORX) shares increased by 25.53% to $2.36. The company's market cap stands at $2.8 million. Innovative Eyewear (NASDAQ:LUCY) stock rose 19.62% to $0.22. The company's market cap stands at $3.8 million. Vaccinex (NASDAQ:VCNX) stock rose 17.86% to $6.07. The market value of their outstanding shares is at $9.6 million. Guardant Health (NASDAQ:GH) shares increased by 15.35% to $26.3. The company's market cap stands at $3.2 billion. Scinai Immunotherapeutics (NASDAQ:SCNI) stock rose 14.63% to $4.22. The co

U.S. stocks traded higher toward the end of trading, with the Nasdaq Composite gaining more than 1% on Friday. The Dow traded up 0.12% to 39,112.74 while the NASDAQ rose 1.08% to 16,917.09. The S&P 500 also rose, gaining, 0.70% to 5,304.78. Check This Out: Top 3 Health Care Stocks That May Crash In May Leading and Lagging SectorsCommunication services shares jumped by 1.3% on Friday. In trading on Friday, health care shares fell by 0.1%. Top Headline The total number of active U.S. oil rigs came in unchanged at 497 rigs this week, Baker Hughes Inc reported. Equities Trading UP                        Akanda Corp. (NASDAQ:AKAN) shares shot up 34% to $3.2001. The inter

Shares of NetEase, Inc. (NASDAQ:NTES) fell during Friday's session after the company reported worse-than-expected first-quarter revenue. NetEase reported fiscal first-quarter 2024 revenue growth of 7.2% year-on-year to $3.72 billion (26.9 billion Chinese yuan), missing the analyst consensus estimate of $3.79 billion. The Chinese gaming player’s adjusted EPADS of $1.81 beat the analyst consensus estimate of $1.79, according to data from Benzinga Pro. NetEase shares declined 4% to $91.02 on Friday. Here are some other stocks moving in today’s mid-day session. Gainers Akanda Corp. (NASDAQ:AKAN) shares climbed 101% to $4.81. The international medical cannabis company implemented

Gainers Innovative Eyewear (NASDAQ:LUCY) shares increased by 328.8% to $0.8 during Friday's regular session. The market value of their outstanding shares is at $13.9 million. OneMedNet (NASDAQ:ONMD) shares increased by 66.66% to $2.45. The market value of their outstanding shares is at $58.4 million. TransCode Therapeutics (NASDAQ:RNAZ) stock rose 28.05% to $1.78. The company's market cap stands at $11.7 million. Onconetix (NASDAQ:ONCO) shares moved upwards by 20.15% to $0.17. The market value of their outstanding shares is at $3.7 million. The company's, Q1 earnings came out 4 days ago. Aptorum Gr (NASDAQ:APM) shares moved upwards by 17.2% to $4.7. The market value of their outstanding